Table 5. Sacubitril/valsartan in failure management guidelines in Asian countries in PARADIGM-HF.
| Country | Most recent year of publication | Name of issuing authority | Sacubitril/valsartan (ARNI) status | |
|---|---|---|---|---|
| East Asia | ||||
| China | 2018 | China Heart Society60) | IB recommendation in patients who have remained symptomatic despite optimal therapy with an ACEI/ARB, a beta-blocker and an MRA. | |
| South Korea | 2017 | Korean guidelines for diagnosis and management of chronic HF61) | Not included in recommendations. | |
| Taiwan | 2012 | Taiwan Society of Cardiology62) | No revised guidelines. | |
| South Asia | ||||
| India | 2018 | Cardiology Society of India63) | In patients who remain symptomatic despite optimal therapy with an ACEI, beta blocker and MRA, ARNI should be considered. | |
| South-East Asia | ||||
| Malaysia | 2014 | Academy of Medicine of Malaysia64) | No revised guidelines. | |
| Philippines | - | - | No revised guidelines. | |
| Thailand | 2019 | HF council of Thailand65),66) | IB recommendation in patients who have remained symptomatic despite optimal therapy with an ACEI/ARB, a beta-blocker and an MRA. | |
| IIbC recommendation for ACEI/ARB naïve patients who may be able to tolerate ARNI. | ||||
| Singapore | 2004 | Ministry of Health67) | No revised guidelines. | |
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with Angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial.